| Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor F Fischetti, P Durigutto, V Pellis, A Debeus, P Macor, R Bulla, F Bossi, ... Blood 106 (7), 2340-2346, 2005 | 428 | 2005 |
| Dynamics of complement activation in aHUS and how to monitor eculizumab therapy M Noris, M Galbusera, S Gastoldi, P Macor, F Banterla, E Bresin, ... Blood, The Journal of the American Society of Hematology 124 (11), 1715-1726, 2014 | 345 | 2014 |
| Complement in human diseases: lessons from complement deficiencies M Botto, M Kirschfink, P Macor, MC Pickering, R Würzner, F Tedesco Molecular immunology 46 (14), 2774-2783, 2009 | 335 | 2009 |
| In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab P Macor, C Tripodo, S Zorzet, E Piovan, F Bossi, R Marzari, A Amadori, ... Cancer research 67 (21), 10556-10563, 2007 | 185 | 2007 |
| A non–complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome C Agostinis, P Durigutto, D Sblattero, MO Borghi, C Grossi, F Guida, ... Blood, The Journal of the American Society of Hematology 123 (22), 3478-3487, 2014 | 152 | 2014 |
| The development of atypical hemolytic uremic syndrome depends on complement C5 EG de Jorge, P Macor, D Paixao-Cavalcante, KL Rose, F Tedesco, ... Journal of the American Society of Nephrology 22 (1), 137-145, 2011 | 135 | 2011 |
| Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement‐regulatory proteins CD55 and CD59 F Ziller, P Macor, R Bulla, D Sblattero, R Marzari, F Tedesco European journal of immunology 35 (7), 2175-2183, 2005 | 115 | 2005 |
| NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation F Pozzo, T Bittolo, F Arruga, P Bulian, P Macor, E Tissino, B Gizdic, ... Leukemia 30 (1), 182-189, 2016 | 114 | 2016 |
| Complement as effector system in cancer immunotherapy P Macor, F Tedesco Immunology letters 111 (1), 6-13, 2007 | 107 | 2007 |
| Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery PL Meroni, P Macor, P Durigutto, L De Maso, M Gerosa, M Ferraresso, ... Blood, The Journal of the American Society of Hematology 127 (3), 365-367, 2016 | 84 | 2016 |
| Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice P Macor, E Secco, N Mezzaroba, S Zorzet, P Durigutto, T Gaiotto, ... Leukemia 29 (2), 406-414, 2015 | 81 | 2015 |
| Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications F Tedesco, MO Borghi, M Gerosa, CB Chighizola, P Macor, PA Lonati, ... Frontiers in immunology 9, 1388, 2018 | 71 | 2018 |
| A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy F Riccardi, M Dal Bo, P Macor, G Toffoli Frontiers in Pharmacology 14, 1274088, 2023 | 61 | 2023 |
| Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity M Fornasier, S Biffi, B Bortot, P Macor, A Manhart, FR Wurm, S Murgia Journal of colloid and interface science 580, 286-297, 2020 | 60 | 2020 |
| Simple scale-up of recombinant antibody production using an UCOE containing vector S Boscolo, F Mion, M Licciulli, P Macor, L De Maso, M Brce, MN Antoniou, ... New Biotechnology 29 (4), 477-484, 2012 | 58 | 2012 |
| Multiple-organ complement deposition on vascular endothelium in COVID-19 patients P Macor, P Durigutto, A Mangogna, R Bussani, L De Maso, S D’Errico, ... Biomedicines 9 (8), 1003, 2021 | 57 | 2021 |
| Complement activated by chimeric anti–folate receptor antibodies is an efficient effector system to control ovarian carcinoma P Macor, D Mezzanzanica, C Cossetti, P Alberti, M Figini, S Canevari, ... Cancer research 66 (7), 3876-3883, 2006 | 57 | 2006 |
| Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5 P Macor, P Durigutto, L De Maso, C Garrovo, S Biffi, A Cortini, F Fischetti, ... Arthritis & Rheumatism 64 (8), 2559-2567, 2012 | 55 | 2012 |
| The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies R Marzari, D Sblattero, P Macor, F Fischetti, R Gennaro, JD Marks, ... European journal of immunology 32 (10), 2773-2782, 2002 | 55 | 2002 |
| The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target L Baboci, S Capolla, F Di Cintio, F Colombo, P Mauro, M Dal Bo, ... Journal of Oncology 2020 (1), 4638192, 2020 | 53 | 2020 |
